Merck-4NCT07240220
The Mother-Daughter Project: Merck-4
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Start date changed from estimate of Feb 1, 2026 to Jul 22, 2026
- Eligibility criteria expanded, about 6 words
- Primary endpoints: details revised at 1 of 4 entries
- Interventions modified
- Study description revised
- Site details revised
Notable Phase: Not specified to Not applicablev2 Show 7 more changesShow less
- Primary completion date: Feb 1, 2028 to Aug 1, 2028
- Eligibility criteria shortened, about 14 words
- Primary endpoints: 1 to 4
- Interventions: 9-valent HPV vaccine (Biological) to Gardisil-9 (Biological), High Risk HPV DNA Testing (Diagnostic Test), Visual Inspection with acetic acid (VIA) and possible cervical biopsy…
- Study description shortened, about 4,008 words
- Study title shortened, about 13 words
- Study arms: 1 to 2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Detection of CIN2/3
Timeframe: Baseline
Local knowledge and attitudes
Timeframe: Baseline and after HPV vaccination of daughters is complete (assessed 2 weeks after second vaccine)
Barriers to participation
Timeframe: During a one-time interview
Factors that influence immunity to the HPV vaccine
Timeframe: 24 months after second HPV vaccine
Arms and interventions
Kenyan womenOther
Up to 500 adult women will undergo cervical cancer screening.
Kenyan daughtersOther
Up to an additional 2000 girls (daughters of participants in the Kenyan women arm) will be immunized against HPV using the 9-valent HPV vaccine (Gardasil-9).
Biologicals: Gardasil-9
Diagnostic tests: High Risk HPV DNA Testing
Procedures: Visual Inspection with acetic acid (VIA) and possible cervical biopsy
Sites
1 site in 1 country
- Moi UniversityEldoret, Kenya